

## SHARP GROWTH IN NET SALES AGAIN

Longjumeau, April 20, 2016

**PCAS (Euronext Paris: PCA)**, a specialist in developing and producing complex molecules for life sciences and innovative technologies, has announced the publication of its consolidated net sales for the 1<sup>st</sup> quarter of 2016.

The PCAS Group's consolidated net sales totaled €45.3 million in the 1<sup>st</sup> quarter of 2016, up by 12.2 % compared to the same period in the previous financial year (+10.2 % at constant exchange rate).

<i>in millions of euros</i>	2016	2015	% change	2016 At a constant exchange rate	% change
<b>Net sales at 31 march</b>	<b>45.3</b>	<b>40.4</b>	<b>12.2 %</b>	<b>44.5</b>	<b>10.2 %</b>
<i>Pharmaceutical Synthesis</i>	<i>30.2</i>	<i>25.7</i>	<i>17.5 %</i>	<i>29.5</i>	<i>14.6 %</i>
<i>Fine specialty chemicals</i>	<i>15.1</i>	<i>14.6</i>	<i>2.9 %</i>	<i>15.0</i>	<i>2.4 %</i>

### Pharmaceutical Synthesis

Pharmaceutical synthesis activities in Health generated €30.2 million, up 17.5 % compared to 2015 (+14.6 % at constant exchange rate), particularly sustained by the Exclusive activity.

### Fine specialty chemicals

Net sales of Fine Specialty Chemicals amounted to €15.1 million, up 2.9 % compared to 2015 (+2.4 % at a constant exchange rate), this activity growing both in Performance Additives and Advanced Specialty Chemicals.

### Outlook for the current year

The company thus confirms its sales growth targets for 2016 as a whole, excluding growth through acquisition, both in Pharmaceutical Synthesis and in Fine Specialty Chemicals.



#### NEXT FINANCIAL DISCLOSURE:

*Net sales of 1<sup>st</sup> half 2016, July 19th, 2016*

### About PCAS

PCAS specialises in the development and production of complex molecules for Life Sciences and Innovative Technologies. With 7% of its turnover dedicated to R&D and a wide international presence, PCAS is the preferred industrial partner of market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments, and also includes two subsidiaries with very strong potential: Protéus in biotechnology and Enersens in high-performance insulation. With a particularly high standard of performance, PCAS achieved net sales of €179.1 million in 2015 and employs nearly 900 people in six countries.

For more information about PCAS: [www.pcas.com](http://www.pcas.com)



---

#### PCAS

#### NewCap

Vincent Touraille / Eric Moissenot  
PCAS

Emmanuel Huynh / Louis-Victor Delouvrier  
NewCap

Financial Communication & investors relations

Tel. : +33 1 69 79 61 32  
[www.pcas.com](http://www.pcas.com)

Tel. : +33 1 44 71 98 53  
[pcas@newcap.eu](mailto:pcas@newcap.eu)